OpenAI introduces language focused on researching the extension of human life
A research organization has partnered with a startup focused on advancing stem cell production techniques. Read Full Article at RT.com.
TroibNews 
The organization has teamed up with a startup to develop methods for improving stem cell production.
OpenAI has introduced a new language model known as GPT-4b micro, tailored to assist scientists in extending human lifespan, as reported by MIT Technology Review. The prominent AI research company is collaborating with Retro Biosciences on an initiative focused on enhancing stem cell production through the re-engineering of specific proteins.
Stem cells play a vital role in regenerative medicine because of their ability to transform into various cell types, which may lead to treatments for age-related conditions.
Founded in 2021, Retro Biosciences is a startup dedicated to increasing human lifespan through cellular reprogramming. OpenAI CEO Sam Altman invested $180 million in the company in 2022.
GPT-4b micro aims to modify Yamanaka factors, proteins that can convert adult cells into stem cells. Early experiments have shown that the proteins redesigned by the model are over 50 times more effective at inducing stem cell production compared to their natural forms.
The model's training involved extensive biological data from various species, allowing it to predict protein structures and interactions with greater precision than conventional methods.
In a recent article, MIT Technology Review quoted one of the model's developers at OpenAI, John Hallman, who stated that “just across the board, the proteins seem better than what the scientists were able to produce by themselves.”
Currently, GPT-4b micro is still in the research phase and is not available to the public. OpenAI plans to share the findings for peer review in the future.
Another developer on the project, Aaron Jaech, expressed to MIT Technology Review that this initiative aims to solidify OpenAI's role in scientific research. He noted that it remains unclear “whether those capabilities will come out to the world as a separate model or whether they’ll be rolled into our mainline reasoning models.”
In 2018, Google created the first version of its AlphaFold, an AI model designed to determine complex 3D protein structures. According to Google DeepMind’s website, AlphaFold can accomplish this task in just minutes and “to a remarkable degree of accuracy.”
Although GPT-4b micro operates in a related field, it employs different methodologies to assist researchers in effectively re-engineering specific proteins.
Recently, multiple research teams worldwide have been leveraging AI to discover new treatments. A study published in Nature suggested that AI-designed proteins could neutralize hazardous snake venom.
In 2022, researchers from the University of Washington School of Medicine and Harvard University revealed that they had trained various image-generating AI models to create new proteins that could facilitate vaccine development and cancer treatments, among other applications.
“The proteins we find in nature are amazing molecules, but designed proteins can do so much more,” remarked David Baker, a biochemistry professor at UW Medicine and a senior author on the study. He was later awarded the 2024 Nobel Prize in Chemistry for his work in computational protein design.
Max Fischer contributed to this report for TROIB News
OpenAI has introduced a new language model known as GPT-4b micro, tailored to assist scientists in extending human lifespan, as reported by MIT Technology Review. The prominent AI research company is collaborating with Retro Biosciences on an initiative focused on enhancing stem cell production through the re-engineering of specific proteins.
Stem cells play a vital role in regenerative medicine because of their ability to transform into various cell types, which may lead to treatments for age-related conditions.
Founded in 2021, Retro Biosciences is a startup dedicated to increasing human lifespan through cellular reprogramming. OpenAI CEO Sam Altman invested $180 million in the company in 2022.
GPT-4b micro aims to modify Yamanaka factors, proteins that can convert adult cells into stem cells. Early experiments have shown that the proteins redesigned by the model are over 50 times more effective at inducing stem cell production compared to their natural forms.
The model's training involved extensive biological data from various species, allowing it to predict protein structures and interactions with greater precision than conventional methods.
In a recent article, MIT Technology Review quoted one of the model's developers at OpenAI, John Hallman, who stated that “just across the board, the proteins seem better than what the scientists were able to produce by themselves.”
Currently, GPT-4b micro is still in the research phase and is not available to the public. OpenAI plans to share the findings for peer review in the future.
Another developer on the project, Aaron Jaech, expressed to MIT Technology Review that this initiative aims to solidify OpenAI's role in scientific research. He noted that it remains unclear “whether those capabilities will come out to the world as a separate model or whether they’ll be rolled into our mainline reasoning models.”
In 2018, Google created the first version of its AlphaFold, an AI model designed to determine complex 3D protein structures. According to Google DeepMind’s website, AlphaFold can accomplish this task in just minutes and “to a remarkable degree of accuracy.”
Although GPT-4b micro operates in a related field, it employs different methodologies to assist researchers in effectively re-engineering specific proteins.
Recently, multiple research teams worldwide have been leveraging AI to discover new treatments. A study published in Nature suggested that AI-designed proteins could neutralize hazardous snake venom.
In 2022, researchers from the University of Washington School of Medicine and Harvard University revealed that they had trained various image-generating AI models to create new proteins that could facilitate vaccine development and cancer treatments, among other applications.
“The proteins we find in nature are amazing molecules, but designed proteins can do so much more,” remarked David Baker, a biochemistry professor at UW Medicine and a senior author on the study. He was later awarded the 2024 Nobel Prize in Chemistry for his work in computational protein design.
Max Fischer contributed to this report for TROIB News
